Filing Flows › Supernus Pharmaceuticals (SUPN) › Q2 2026 › vs Q2 2025
Supernus Pharmaceuticals (SUPN) Q2 2026 vs Q2 2025 (year over year)
Supernus Pharmaceuticals's revenue rose $53.6M (+32%) from $165M in Q2 2025 to $219M in Q2 2026. The biggest changes: Net product sales +$45.4M (+38%); ONAPGO +$11.9M (+745%); Other −$4.7M (-71%).
Supernus Pharmaceuticals, Q2 2026: revenue $219M (+32% year over year), operating margin -26.5%, net loss $58.4M, operating cash flow −$4.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Qelbree | $89.2M | $77.5M | $11.7M | +15% |
| Collaboration revenue (ZURZUVAE) | $35.4M | $0 | $35.4M | — |
| Royalty, licensing, and other revenues | $18.0M | $7.5M | $10.5M | +141% |
| Oxtellar XR | $8.8M | $11.6M | −$2.9M | -25% |
| Trokendi XR | $8.4M | $11.2M | −$2.8M | -25% |
| APOKYN | $6.3M | $12.8M | −$6.5M | -51% |
| Net product sales | $166M | $121M | $45.4M | +38% |
| GOCOVRI | $37.5M | $36.7M | $870K | +2% |
| ONAPGO | $13.5M | $1.6M | $11.9M | +745% |
| Other | $1.9M | $6.5M | −$4.7M | -71% |
| Revenue | $219M | $165M | $53.6M | +32% |
| Net loss | $58.4M | −$22.5M | $80.9M | — |
| Costs & expenses | $278M | $176M | $102M | +58% |
| Operating costs | $277M | $153M | $124M | +81% |
| Income tax | $723K | −$5.8M | $6.6M | — |
| Cost of revenue | $33.7M | $16.8M | $16.8M | +100% |
| Research & development | $29.5M | $22.1M | $7.3M | +33% |
| SG&A | $134M | $93.6M | $40.1M | +43% |
| Other operating costs | $80.3M | $20.8M | $59.4M | +285% |
| Operating cash sources | $58.4M | −$22.5M | $80.9M | — |
| Depreciation & amortization | $25.7M | $21.4M | $4.4M | +21% |
| Share-based compensation | $8.6M | $7.5M | $1.1M | +15% |
| Working capital & other | $19.2M | $7.2M | $12.0M | +167% |
| Cash used in operations | $4.8M | −$58.5M | $63.3M | — |
| Net loss absorbed | $58.4M | −$22.5M | $80.9M | — |
Questions
How much did Supernus Pharmaceuticals's revenue grow year over year in Q2 2026?
Supernus Pharmaceuticals's revenue rose $53.6M (+32%) from $165M in Q2 2025 to $219M in Q2 2026.
What drove Supernus Pharmaceuticals's revenue change in Q2 2026?
Net product sales +$45.4M (+38%); ONAPGO +$11.9M (+745%); Other −$4.7M (-71%).